News
SNSE
1.790
+8.48%
0.140
Weekly Report: what happened at SNSE last week (0429-0503)?
Weekly Report · 7h ago
Sensei Biotherapeutics Inc <SNSE.OQ> expected to post a loss of 28 cents a share - Earnings Preview
Sensei Biotherapeutics Inc expected to post a loss of 28 cents a share. The company is expected to report results on May 7. The average analyst rating on the shares is "strong buy" and the median 12-month price target is $4.00.
Reuters · 3d ago
CTMX, HSDT and SNSE are among premarket gainers
On the Move CTMX, HSDT and SNSE are among premarket gainers. El Pollo Loco (LOCO) reports upbeat Q1 results, comp restaurant sales beat expectations. Helius Medical Technologies (HSDT) reports a 53% rise.
Seeking Alpha · 3d ago
JAGX, SNSE and BON among mid-day movers
Seeking Alpha · 4d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Emergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's, Q1 earnings came out yesterday. Nuwellis (NASDAQ:NUWE) and Sensei Biotherapeutics also moved upwards. Accuray and Metagenomi were among the losers.
Benzinga · 4d ago
Weekly Report: what happened at SNSE last week (0422-0426)?
Weekly Report · 04/29 12:56
Sensei Biotherapeutics To Present Topline Clinical Data From The SNS-101 Phase I Dose Escalation Study At The 2024 ASCO Annual Meeting
Sensei Biotherapeutics, Inc. Is a clinical stage immuno-oncology company. SNS-101 is a human antibody targeting the immune checkpoint VISTA. The data will be presented in a poster presentation at the 2024 American Society of Clinical Oncology.
Benzinga · 04/24 20:52
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
Sensei Biotherapeutics, Inc. Is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapies for cancer patients. Data from the Phase 1/2 trial of SNS-101 will be presented at the 2024 American Society of Clinical Oncology.
Barchart · 04/24 15:05
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 04/22 20:31
Weekly Report: what happened at SNSE last week (0415-0419)?
Weekly Report · 04/22 12:37
Weekly Report: what happened at SNSE last week (0408-0412)?
Weekly Report · 04/15 12:27
Sensei Biotherapeutics Extends Relationship with Former CFO
TipRanks · 04/12 20:43
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
Sensei Biotherapeutics, Inc. Is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients. Company management will participate in a panel at Canaccord Genuity’s Horizons in Oncology Virtual Conference on April 15th.
Barchart · 04/09 06:30
Weekly Report: what happened at SNSE last week (0401-0405)?
Weekly Report · 04/08 12:33
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism Of Action Of SNS-101 Selectively Targeting The Active Form Of VISTA Within The Tumor Microenvironment
Sensei Biotherapeutics' SNS-101 is designed to target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation. The company has published a peer-reviewed research paper in Nature Communications. Sensei is a clinical stage immuno-oncology company focused on the discovery and development of cancer patients.
Benzinga · 04/04 20:10
Sensei Biotherapeutics CFO Erin Colgan Resigns Amicably
TipRanks · 04/02 12:02
Sensei Biotherapeutics CFO To Resign All Positions With Co Effective April 10
Benzinga · 04/02 11:48
SENSEI BIOTHERAPEUTICS INC - ON MARCH 27, ERIN COLGAN NOTIFIED CO OF HER RESIGNATION FROM ALL POSITIONS WITH COMPANY, INCLUDING AS CFO
Reuters · 04/02 11:46
SENSEI BIOTHERAPEUTICS INC - COLGAN'S RESIGNATION WILL BE EFFECTIVE APRIL 10, 2024
Reuters · 04/02 11:46
Weekly Report: what happened at SNSE last week (0325-0329)?
Weekly Report · 04/01 12:29
More
Webull provides a variety of real-time SNSE stock news. You can receive the latest news about Sensei Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SNSE
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.